Nausea on tirzepatide is driven mostly by delayed gastric emptying, which keeps food in the stomach longer, and by direct signaling to appetite and nausea centers in the brainstem rather than by any irritation of the stomach lining
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
Even with insurance, cost-related nonadherence remains prevalent, with patients often skipping doses, delaying fills, or not obtaining needed medications due to cost [133, 134]
These events were likely linked to the rapid weight loss induced by semaglutide, which is known to increase the risk of biliary complications
There is no comparable human dataset